Version 1
: Received: 17 September 2024 / Approved: 17 September 2024 / Online: 17 September 2024 (10:51:17 CEST)
How to cite:
Braha, A.; Timar, B.; Ivan, V.; Balica, M. M.; Dăniluc, L.; Timar, R. Novel Biomarkers of Grade I Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Preprints2024, 2024091312. https://doi.org/10.20944/preprints202409.1312.v1
Braha, A.; Timar, B.; Ivan, V.; Balica, M. M.; Dăniluc, L.; Timar, R. Novel Biomarkers of Grade I Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Preprints 2024, 2024091312. https://doi.org/10.20944/preprints202409.1312.v1
Braha, A.; Timar, B.; Ivan, V.; Balica, M. M.; Dăniluc, L.; Timar, R. Novel Biomarkers of Grade I Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Preprints2024, 2024091312. https://doi.org/10.20944/preprints202409.1312.v1
APA Style
Braha, A., Timar, B., Ivan, V., Balica, M. M., Dăniluc, L., & Timar, R. (2024). Novel Biomarkers of Grade I Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Preprints. https://doi.org/10.20944/preprints202409.1312.v1
Chicago/Turabian Style
Braha, A., Larisa Dăniluc and Romulus Timar. 2024 "Novel Biomarkers of Grade I Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease" Preprints. https://doi.org/10.20944/preprints202409.1312.v1
Abstract
Background/aims: Prior research identified a significant association between heart disease and metabolic dysfunction-associated liver steatohepatitis (MASLD), but the mechanisms are unclear. This study aims to search predictive biomarkers for grade I left ventricular diastolic dysfunction (LVDD), an early stage of heart failure (HF), in type 2 diabetes mellitus (T2DM) patients. Methods: This single-center, prospective observational study screened 73 T2DM patients for grade 1 LVDD and MASLD using 2D echocardiography, tissue analysis, spectral color Doppler, and Fibromax. Results: The study analyzed 50 patients (mean age 58±11.3 years) with a median diabetes duration of 7 years, abdominal obesity (mean BMI 34.4±5.9 kg/m2), and a mean HbA1c of 7.9±1.5%. The prevalence of grade I LVDD, fibrosis, mild steatosis, moderate to severe liver steatosis, mild MASLD, and moderate MASLD was 54%, 44%, 14%, 80%, 43%, and 34%, respectively. Regression analysis revealed that grade 1 LVDD was positively associated with age, Fibrotest, ɑ2-macroglobulin, epicardiac adipose tissue (EAT), and negatively associated with lateral s`, E wave, E/e`, E/A, medium E`, and septal e` (p< 0.05 for all). ɑ2-macroglobulin > 1.92 g/L (AUROC= 0.782, sensitivity 70.4%, specificity 81.2%) and fibrotest score > 0.11 (AUROC 0.766, sensitivity 92.6%, specificity 56.2%) were significant predictors of grade I LVDD. Conclusion: HF is a multifaceted disorder associated with multisystem organ damage, including nonalcoholic MASLD. Although the underlying mechanisms remain unclear, innovative non-invasive biomarkers, such as ɑ2-macroglobulin or fibrotest, could concurrently indicate liver stiffness and the likelihood of grade I LVDD, an early, asymptomatic HF stage in T2DM patients.
Keywords
predictive biomarkers; left ventricular diastolic dysfunction; metabolic dysfunction-associated liver steatohepatitis; type 2 diabetes mellitus
Subject
Medicine and Pharmacology, Endocrinology and Metabolism
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
